In vivo Drug Efficacy Monitoring
In Vivo Monitoring of Drug Efficacy & Action
- • IVIM Technology’s contract R&D service provides a direct imaging analysis of delivery to target tissue and cells, efficacy, and mode of action (MOA) of new therapeutic candidates in microscopic cellular-level in various preclinical model of human disease.
Therapeutic Candidates Facilitating or Inhibiting Angiogenesis
Vessel normalization by anti-angiogenic therapeutic candidates
- • Disease model : Tumor, acute/chronic inflammation, retinopathy, etc.
- • Therapeutic candidates : Anti-tumor, anti-inflammatory drug, etc.
- • Observations : Changes in vessel morphology, vessel diameter, vessel density, vascular permeability, blood flow rate, etc.
Tumor
Vehicle, Day 7
Vessel
Lung cancer cell
![](/assets/img/applications/a-57.jpg)
Vehicle, Day 13
![](/assets/img/applications/a-58.jpg)
Vehicle, Day 13
![](/assets/img/applications/a-59.jpg)
Tumor
Drug, Day 7
Vessel
Lung cancer cell
![](/assets/img/applications/a-60.jpg)
Drug, Day 13
![](/assets/img/applications/a-61.jpg)
Drug, Day 13
![](/assets/img/applications/a-62.jpg)
![](/assets/img/applications/a-63.jpg)
![](/assets/img/applications/a-64.jpg)
Angiogenesis in target cell transplanted site or ischemic regions
- • Disease model : Ischemia-reperfusion injury model, islet cell/stem cell transplantation model, etc.
Kidney
Vessel
Islet graft
![](/assets/img/applications/a-65.jpg)
![](/assets/img/applications/a-66.jpg)
Anti-inflammatory Therapeutic Candidates
Efficacy monitoring & MOA validation of anti-inflammatory therapeutic candidates
- • Disease model : Acute/chronic inflammation model, tumor model, etc.
- • Observations : Changes in microcirculation, tissue cell apoptosis, immune cell recruitment/motility/activity (phagocytosis), etc.
- • Tissue cells : Vascular endothelial cells, lymphatic endothelial cell, hepatocyte, kidney cell, astrocyte, etc.
- • Immune cells : Granulocyte, macrophage, neutrophil, dendritic cell, monocyte, microglial cell, NK cell, etc.
Pre-Drug
Neutrophil
RBC
Vessel
![](/assets/img/applications/a-67.jpg)
Post-Drug
![](/assets/img/applications/a-68.jpg)
Pre-Drug
RBC
![](/assets/img/applications/a-69.jpg)
Post-Drug
![](/assets/img/applications/a-70.jpg)
Quantitative comparison of groups
Lung
Sham
Merge
![](/assets/img/applications/a-71.jpg)
Neutrophil
![](/assets/img/applications/a-72.jpg)
RBC
![](/assets/img/applications/a-73.jpg)
Vessel
![](/assets/img/applications/a-74.jpg)
Vehicle
Merge
![](/assets/img/applications/a-75.jpg)
Neutrophil
![](/assets/img/applications/a-76.jpg)
RBC
![](/assets/img/applications/a-77.jpg)
Vessel
![](/assets/img/applications/a-78.jpg)
Drug
Merge
![](/assets/img/applications/a-79.jpg)
Neutrophil
![](/assets/img/applications/a-80.jpg)
RBC
![](/assets/img/applications/a-81.jpg)
Vessel
![](/assets/img/applications/a-82.jpg)
![](/assets/img/applications/a-83.jpg)
![](/assets/img/applications/a-84.jpg)
![](/assets/img/applications/a-85.jpg)
Efficacy Monitoring of Other Therapeutic Candidates
Changes in tumor cell growth/death/metastasis after treatment of anti-tumor therapeutic candidates
Changes in fibrotic collagen deposition & immune cell recruitment after treatment of anti-fibrotic therapeutic candidates
Changes in drug delivery, uptake & absorption
Changes in fibrotic collagen deposition & immune cell recruitment after treatment of anti-fibrotic therapeutic candidates
Changes in drug delivery, uptake & absorption